CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sesen Bio (Nasdaq:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Company management will host a conference call and webcast on Monday, May 13, 2019 at 8:00 a.m. EDT to review operating results for the first quarter ended March 31, 2019 and updated, preliminary primary and new secondary endpoint data from the Phase 3 VISTA trial of Vicinium® for patients with h

Source link